<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542124</url>
  </required_header>
  <id_info>
    <org_study_id>NM-ONC-001</org_study_id>
    <secondary_id>1R44CA192576-01</secondary_id>
    <nct_id>NCT02542124</nct_id>
  </id_info>
  <brief_title>NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)</brief_title>
  <official_title>A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL-12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neumedicines Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Neumedicines Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study, NM-IL-12 will be evaluated as immunotherapy to increase antitumor&#xD;
      efficacy against CTCL, while reducing skin-related toxicity, when combined with low-dose&#xD;
      TSEBT therapy. Determination of the maximum tolerated dose (MTD) for NM-IL-12 is not planned&#xD;
      in this study, rather, a pre-defined starting dose will be explored; this dose is based on&#xD;
      two safety and tolerability studies of NM-IL-12 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open-label, non-randomized study with NM-IL-12 dosed in combination&#xD;
      with low dose TSEBT in CTCL patients. This study is planned to be conducted in 10 patients,&#xD;
      18 years or older in age, undergoing low dose TSEBT of 12 Gy over a 3-week period.&#xD;
&#xD;
      The study will initially enroll 4 patients and then will be expanded to enroll 6 additional&#xD;
      patients (total 10 patients) depending on the presence or absence of Dose Modifying Criteria&#xD;
      (DMC). Decision whether to de-escalate will be made after first 4 patients are followed up&#xD;
      for 28 days from the first dose of NM-IL-12.&#xD;
&#xD;
      Safety monitoring will continue throughout the whole period of drug administration and the&#xD;
      treatment will be discontinued if intolerable toxicity or disease progression occurs during&#xD;
      this period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be evaluated on the basis of the following parameters (Vital signs, physical examination,Toxicity according to the NCI CTCAE, Immunogenicity evaluated by the presence of anti-drug antibody) :</measure>
    <time_frame>107 weeks</time_frame>
    <description>General safety: Vital signs (temperature, blood pressure, pulse rate, respiratory rate) and physical examination.&#xD;
Toxicity according to the NCI CTCAE (v4.03) for AEs and clinical laboratory profile; AEs will be collected in all patients who received at least one dose of NM-IL-12 and up to four weeks post last NM-IL-12 dose.&#xD;
Immunogenicity of NM-IL-12 will be evaluated by the presence of anti-drug antibody (ADA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response measured by a modified severity-weighted assessment tool (mSWAT)</measure>
    <time_frame>107 weeks</time_frame>
    <description>Exploratory skin clinical responses measured by a modified severity-weighted assessment tool (mSWAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>107 weeks</time_frame>
    <description>Progression free survival based on every 4 week follow up after the monthly dose until one of the events below occurs first:&#xD;
Progressive disease is documented&#xD;
Another treatment for CTCL is administered (topical or systemic)&#xD;
107 weeks are completed after the patient's first dose of NM-IL-12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cutaneous T Cell Lymphoma (CTCL)</condition>
  <condition>Mycosis Fungoides</condition>
  <condition>Sézary Syndrome</condition>
  <arm_group>
    <arm_group_label>NM-IL-12 and TSEBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSEBT and subcutaneous doses of NM-IL-12</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NM-IL-12 and TSEBT</intervention_name>
    <description>The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.</description>
    <arm_group_label>NM-IL-12 and TSEBT</arm_group_label>
    <other_name>HemaMax, rHu-IL12, LD-TSEBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older&#xD;
&#xD;
          2. Biopsy-confirmed CD4+ mycosis fungoides or Sézary syndrome, stage IB to IIIB&#xD;
&#xD;
          3. The patient is eligible for TSEBT&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) of ≤ 2.&#xD;
&#xD;
          5. Adequate bone marrow function: WBC &gt; 2000/μL; platelet count &gt; 75,000/μL; Neutrophil&#xD;
             count &gt; 1000/μL, without use of colony stimulating factors (CSF).&#xD;
&#xD;
          6. Required washout period for prior therapies Topical therapy: 2 weeks&#xD;
&#xD;
               -  Phototherapy (PUVA): 4 weeks&#xD;
&#xD;
               -  Local Skin Radiation Therapy (&lt; 10% skin surface): 4 weeks&#xD;
&#xD;
               -  Retinoids: 4 weeks&#xD;
&#xD;
               -  Interferons: 4 weeks&#xD;
&#xD;
               -  Low dose methotrexate: 4 weeks&#xD;
&#xD;
               -  HDAC inhibitors: 8 weeks&#xD;
&#xD;
          7. Women of child-bearing potential must have negative serum pregnancy test and use&#xD;
             accepted highly effective methods of birth control throughout the study and for 90&#xD;
             days after dosing and must agree to use effective contraception.&#xD;
&#xD;
          8. Male patients must be willing to use an appropriate method of contraception (e.g.,&#xD;
             condoms) or abstain from sexual intercourse and inform any sexual partners that they&#xD;
             must also use a reliable method of contraception during the study and for 90 days&#xD;
             after dosing.&#xD;
&#xD;
          9. Adequate hepatic function: bilirubin ≤1.5 x upper limit of normal (ULN), AST ≤2.5 x&#xD;
             ULN, ALT ≤2.5 x ULN, alkaline phosphatase (liver fraction) ≤2.5 x ULN&#xD;
&#xD;
         10. Adequate renal function: creatinine ≤1.5 x ULN&#xD;
&#xD;
         11. Ability to comply with the treatment schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Biopsy confirmed CD8+ CTCL histology&#xD;
&#xD;
          2. Large cell transformation&#xD;
&#xD;
          3. Prior systemic use of any immunosuppressive chemotherapy (except low dose&#xD;
             methotrexate) and/or monoclonal antibody treatment for CTCL&#xD;
&#xD;
          4. Prior courses of TSEBT (Note: localized skin-directed radiotherapy is allowed if&#xD;
             administered at least 4 weeks prior to initiation on study).&#xD;
&#xD;
          5. Concomitant use of any anti-cancer therapy or immune modifier.&#xD;
&#xD;
          6. Prior allogeneic hematopoietic cell transplant.&#xD;
&#xD;
          7. Any ongoing infection whether receiving or not receiving antibiotics or have received&#xD;
             intravenous antibiotics, antiviral, or antifungal agents within 2 weeks prior to the&#xD;
             start of the study drug.&#xD;
&#xD;
          8. Known history of human immunodeficiency virus (HIV), hepatitis B or C&#xD;
&#xD;
          9. For women on estrogen based contraceptives, family history of venous thromboembolism&#xD;
             (VTE) and/or risk factors predisposing for VTE and other medical conditions known to&#xD;
             be associated with VTE.&#xD;
&#xD;
         10. History of prior malignancy with the exception of cervical intraepithelial neoplasia,&#xD;
             non-melanoma skin cancer, and adequately treated localized prostate carcinoma (PSA&#xD;
             &lt;1.0). Patients with a history of other malignancies must have undergone potentially&#xD;
             curative therapy and have no evidence of that disease for five years&#xD;
&#xD;
         11. Uncontrolled intercurrent illness, condition, or circumstances that could limit&#xD;
             compliance with the study, including, but not limited to the following: acute or&#xD;
             chronic graft versus host disease, uncontrolled diabetes mellitus or hypertension, or&#xD;
             psychiatric conditions&#xD;
&#xD;
         12. Any other medical issue, including laboratory abnormalities, deemed by the&#xD;
             Investigator to be likely to interfere with patient participation&#xD;
&#xD;
         13. Unresolved toxicity from previous anticancer therapy or incomplete recovery from&#xD;
             surgery&#xD;
&#xD;
         14. Major surgery within 12 weeks of enrolment&#xD;
&#xD;
         15. Medically significant cardiac event or unstable cardiovascular function defined as:&#xD;
&#xD;
               -  Symptomatic ischemia, unstable angina pectoris&#xD;
&#xD;
               -  Uncontrolled clinically significant cardiac arrhythmia&#xD;
&#xD;
               -  Symptomatic heart failure NYHA Class ≥ 3&#xD;
&#xD;
               -  Myocardial infarction or cardiac surgery within 6 months prior to enrollment&#xD;
&#xD;
         16. Cerebrovascular event (transient ischemic attack, stroke or CNS bleeding) within the&#xD;
             last 12 months.&#xD;
&#xD;
         17. Major bleeding within the last 6 months.&#xD;
&#xD;
         18. Use of any investigational agents within 30 days prior to enrollment and for the&#xD;
             duration of the study&#xD;
&#xD;
         19. Pregnant or lactating&#xD;
&#xD;
         20. Unwilling or unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youn H Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ehoonline.org/content/3/1/11</url>
    <description>Single Low-dose rHuIL-12 Safely Triggers Multilineage Hematopoietic and Immune-mediated Effects.</description>
  </link>
  <reference>
    <citation>Gokhale MS, Vainstein V, Tom J, Thomas S, Lawrence CE, Gluzman-Poltorak Z, Siebers N, Basile LA. Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects. Exp Hematol Oncol. 2014 Apr 11;3(1):11. doi: 10.1186/2162-3619-3-11.</citation>
    <PMID>24725395</PMID>
  </reference>
  <reference>
    <citation>Gluzman-Poltorak Z, Vainstein V, Basile LA. Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: evidence for the development of a frontline radiation medical countermeasure. Am J Hematol. 2014 Sep;89(9):868-73. doi: 10.1002/ajh.23770. Epub 2014 Jun 19.</citation>
    <PMID>24852354</PMID>
  </reference>
  <reference>
    <citation>Gluzman-Poltorak Z, Mendonca SR, Vainstein V, Kha H, Basile LA. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation. J Hematol Oncol. 2014 Apr 6;7:31. doi: 10.1186/1756-8722-7-31.</citation>
    <PMID>24708888</PMID>
  </reference>
  <reference>
    <citation>Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gill K, Mar V, Mendonca S, Miller JD, Tom J, Trinh A, Gallaher TK. HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS One. 2012;7(2):e30434. doi: 10.1371/journal.pone.0030434. Epub 2012 Feb 24.</citation>
    <PMID>22383962</PMID>
  </reference>
  <reference>
    <citation>Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999 Aug 1;94(3):902-8.</citation>
    <PMID>10419880</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTCL</keyword>
  <keyword>Total Skin Electron Beam Therapy (TSEBT)</keyword>
  <keyword>Mycosis fungoides</keyword>
  <keyword>Sézary syndrome</keyword>
  <keyword>recombinant human Interleukin-12 (rHuIL-12)</keyword>
  <keyword>T Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

